Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL793097 | 0.72 | CYP2A6 (0.50) | HTR6 | |
| SCHEMBL14896280 | 0.69 | OXER1 (0.40) | HTR6 | |
| SCHEMBL21275794 | 0.68 | CDK4 (0.42) | HTR6 | |
| SCHEMBL8259764 | 0.67 | HTR6 (0.40) | HTR6 | |
| SCHEMBL30329138 | 0.66 | ALDH1A1 (0.32) | HTR6 | |
| SCHEMBL30357699 | 0.66 | LMNA (0.48) | — | |
| SCHEMBL2263563 | 0.66 | LMNA (0.48) | — | |
| SCHEMBL31142624 | 0.65 | HTR6 (0.31) | HTR6 | |
| SCHEMBL30615201 | 0.64 | LMNA (0.46) | — | |
| SCHEMBL2263247 | 0.64 | LMNA (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562898-B2 | Substituted benzenesulfonamides as inhibitors of alpha-4 beta-7 integrin activity | EA PHARMA CO., LTD. (JP) | 2020-02-18 | — | — | US | disclosed |
| US-20190040059-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | EA PHARMA CO., LTD. (JP) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562898-B2 | Substituted benzenesulfonamides as inhibitors of alpha-4 beta-7 integrin activity | ITGB4, ITGB7, ITGA4 | HTR6 2252/4885 |
| US-20190040059-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ITGB4, ITGB5, ITGA4 | HTR6 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.